Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer

Investigational New Drugs

Volumn 16, Issue 2, 1998, Pages 179-182

  Edelman, Martin J ^a,b   Meyers, Frederick J ^b   Grennan, Tim ^c   Lauder, Jun ^b   Doroshow, James ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c KAISER PERMANENTE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Hormone refractory; Phase II trial; Prostate cancer; Pyrazine diazohydroxide

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; PYRAZINE DIAZOHYDROXIDE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0031761823     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006097109088     Document Type: Article

References (14)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. Ca Cancer J Clin 47: 5-27, 1997
2. Roth BJ: Combination chemotherapy in advanced prostate carcinoma: a silk purse. J Clin Oncol 12: 2001-2002, 1994
3. Plowman J, Haugwitz RD, Narayanan VL, Baker DC, Hand ES, Rampal JB, Safavy A: Preclinical antitumor activity of pyrazine diazohydroxide, NSC 361456. Proc Amer Assoc Cancer Res 27: 275(#1089), 1986
4. Brodfuehrer JI, Moore DJ, Melder DC, Wilke TJ, Powis G: In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal co-incubation. Invest New Drugs 6: 3-9, 1988
5. Supko JG, Balcerak SP, Kraut EH: Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous infusion in patients with advanced solid tumors. Can Res 53: 4843-4849, 1993
6. Vogelzang NJ, Mick R, Janisch L et al.: Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Can Res 54: 114-119, 1994
7. Dhodapkar MV, Richardson RL, Reid JM and Ames MM: Pyrazine diazohydroxide (NSC-361456): Phase I clinical and pharmacokinetic studies. Invest New Drugs 12: 207-216, 1994
8. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353, 1961
9. Harrison SD, Plowman J, Dykes DJ, Waud WR, Griswold DP Jr: Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo. Can Chemo Pharmacol 25: 425-429, 1990
10. Kelly WK, Scher HI, Mazumdar M et al.: Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol 11: 607-615, 1993
11. Sridhara R, Eisenberger MA, Sinibaldi VJ et al.: Evaluation of prostate-specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy. J Clin Oncol 13: 2944-2953, 1995
12. Thalmann GN, Sikes RA, Chang S et al.: Suramin induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88: 794-801, 1996
13. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996
14. Raghavan D: Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drags. Semin Oncol 15: 371-389, 1988